Key Insights from the BeAT-HF Trial at DGK Mannheim 2023 

At DGK Mannheim 2023, Dr. Michael Zile presented the results of the BeAT-HF study. The trial evaluated the safety, efficacy, and outcomes of Baroreflex Activation Therapy (BAT) for the treatment of patients with heart failure and reduced ejection fraction. Expanding on the pre-market phase data, the totality of evidence from the BeAT-HF post-market study shows long-term benefits for patients with heart failure.

Watch Dr. Michael Zile present the outcomes of the BeAT-HF trial.

The HCPs involved in this symposium have received compensation from CVRx for their participation.